BioCentury
ARTICLE | Clinical News

Ronopterin: Phase III started

September 12, 2016 7:00 AM UTC

vasopharm began the double-blind, placebo-controlled, European Phase III NOSTRA III trial to evaluate 17 mg/kg IV ronopterin given over 48 hours in 232 patients who suffered a moderate to severe TBI w...